Ovarian cancer is the fifth most common cancer in women. It is often detected at an advanced stage, which generally results in a poor prognosis and survival rate. Early detection is the key to improved survival among women

There is no one screening test considered reliable enough to look for ovarian cancer in the general population. The two main tests used in screening are the serum tumour marker CA125 and transvaginal ultrasound.

A new marker HE4 has now been identified for ovarian carcinoma. There is mounting evidence that use of a dual test, utilising both CA125 and HE4, would be able to detect ovarian cancers at an earlier stage.

This combination blood test is now available at the Courtfield Private Practice. We suggest that women with a family history of cancer and women over the age of 40 have this test. If you would like further information, please don’t hesitate to talk to Dr Jill Harling.